Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication

Phase 3 Completed 352 enrolled National Cancer Center, Korea

RandomizedParallel-groupOpen-labelTreatment

Summary

In this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple therapy in comparison with that of 7-day PPI-based standard triple as 1st line treatment for H. pylori.

Timeline

Start: 2015-09
Primary completion: 2018-12
Completion: 2019-09-28

Outcome

Met primary endpoint

paper The BQT-group achieved a significantly higher eradication rate than the STT-group in the intention-to-treat analysis (74.3% vs 57.1%, respectively; P = 0.001) PMID 33653284 ↗

Publications

Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol. 2021 Mar 2;21(1):95. doi: 10.1186/s12876-021-01680-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amoxicillin	Other / unclassified	1000 mg	—
Comparator	Bismuth Potassium Citrate	Unknown	300 mg	—
Subject	Clarithromycin	Small molecule	500 mg	—
Subject	Lansoprazole	Other / unclassified	30 mg	—
Subject	Metronidazole	Small molecule	500 mg	—
Subject	Tetracycline	Unknown	500 mg	—